MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
The Pharma Data
JANUARY 13, 2021
These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), (..)
Let's personalize your content